Biotech Values

[Whalatane]

AMRN 13 D
https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=116752874&type=HTML&symbol=AMRN&companyName=Amarin+Corporation+plc&formType=SC+13D%2FA&formDescription=%5BAmend%5D+General+statement+of+acquisition+of+beneficial+ownership&dateFiled=2022-06-03&CK=897448

Item 4. Purpose of Transaction. Item 4 of the Schedule 13D is hereby amended to include the following:
The Reporting Persons have had discussions with the Issuer and other interested parties about ways to maximize the value of the Issuer’s assets. More recently, the Reporting Persons discussed with the Issuer the disappointing first quarter results. The Reporting Persons believe that the meaningful decrease in Share price following the earnings announcement reflects the Issuer’s insufficient adjustment to changing market conditions for its key drug Vascepa and investor concerns about the ability of leadership as currently constituted to navigate the Issuer during this critical time. The Reporting Persons believe that the expertise and experience of its principals would be extremely beneficial to the Issuer and intend to seek representation on the Issuer’s board of directors. The Reporting Persons believe the Shares continue to be significantly undervalued.
The Reporting Persons thank the many shareholders who have reached out to them seeking guidance on how to vote at the Issuer’s upcoming annual meeting.
The Reporting Persons will disclose their intentions with respect to the Issuer’s upcoming annual meeting, including how they intend to vote their shares, following the outcome of the ongoing discussions with the Issuer.

Sarissa Capital is an activist hedge fund lead by Dr Denner ...ex Ichan employee
Denner got control of MDCO and engineered sale to NVS.
I expect a similar action re EU /UK AMRN operations once reimbursement decisions are known
JMO

Kiwi